Literature DB >> 19643778

How Medicare could get better prices on prescription drugs.

Kevin Outterson1, Aaron S Kesselheim.   

Abstract

Congress may reform drug pricing policies under Medicare Part D as part of a larger health reform effort. Currently, the "noninterference" provision prevents the government from negotiating drug prices on behalf of Medicare Part D prescription drug plans. Commonly considered reform proposals borrow ideas from Medicaid, either through returning dual eligibles to Medicaid drug pricing or by imposing mandatory rebates across the Part D population. We examine a menu of other options, including value-based pricing; expansion of generic and therapeutically equivalent substitution; increased formulary diversity; importation; and limited antitrust waivers. These latter options may reduce federal spending without direct government price negotiations.

Mesh:

Substances:

Year:  2009        PMID: 19643778     DOI: 10.1377/hlthaff.28.5.w832

Source DB:  PubMed          Journal:  Health Aff (Millwood)        ISSN: 0278-2715            Impact factor:   6.301


  4 in total

1.  Medicare Part D payments for neurologist-prescribed drugs.

Authors:  Lindsey B De Lott; James F Burke; Kevin A Kerber; Lesli E Skolarus; Brian C Callaghan
Journal:  Neurology       Date:  2016-03-23       Impact factor: 9.910

2.  The prevalence and cost of unapproved uses of top-selling orphan drugs.

Authors:  Aaron S Kesselheim; Jessica A Myers; Daniel H Solomon; Wolfgang C Winkelmayer; Raisa Levin; Jerry Avorn
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

3.  Regulatory Solutions to the Problem of High Generic Drug Costs.

Authors:  Jing Luo; Ameet Sarpatwari; Aaron S Kesselheim
Journal:  Open Forum Infect Dis       Date:  2015-11-13       Impact factor: 3.835

4.  Branded prescription drug spending: a framework to evaluate policy options.

Authors:  Jeromie Ballreich; G Caleb Alexander; Mariana Socal; Taruja Karmarkar; Gerard Anderson
Journal:  J Pharm Policy Pract       Date:  2017-10-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.